Country
United States
Cancer incidence and mortality for United States as published by the source registry: per site group, per year and sex, with age-standardized rates where the source provides them. Population statistics describe groups, never individuals.
- ISO 3166-1
- USA · US
- WHO region
- WHO Region of the Americas
- Population
- not seeded — CancerIndex shows only rates and counts published by the source
- Years covered
- 1999–2024
- Cancer entities
- 36
- Estimate types
- observed
Summary
2024 · Female · all ages
Totals across all cancer sites are shown only when the source publishes an all-sites row. Otherwise the per-site figures below stand on their own; CancerIndex never sums site groups (definitions overlap between sources).
- Deathshighest site group:Malignant Lung Neoplasm61,665countcdc-wonderProvenance
- Source
- CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)
- Dataset
- CDC WONDER Underlying Cause of Death, 2018-2024, Single Race
- Version
- D158 vintage 2024
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
- Run
- ING-CDCWONDER-20260908-000001
- New caseshighest site group (2023, latest available):Malignant Breast Neoplasm288,494countcdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- Mortality rate (age-standardized)highest site group:Malignant Lung Neoplasm24.6per 100,000cdc-wonderProvenance
- Source
- CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)
- Dataset
- CDC WONDER Underlying Cause of Death, 2018-2024, Single Race
- Version
- D158 vintage 2024
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
- Run
- ING-CDCWONDER-20260908-000001
- Incidence rate (age-standardized)highest site group (2023, latest available):Malignant Breast Neoplasm135.2per 100,000cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
No all-sites total in source for this scope — per-site figures below; no national total is computed.
Top cancers
By deaths
2024 · Female · all ages · 36 site groups
| # | Cancer | Deaths (count) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Lung NeoplasmCancer | 61,665 | — | observed | #1 of 28 | C33-C34 | cdc-wonderObserved |
| 2 | Malignant Breast NeoplasmCancer Family | 43,402 | — | observed | #2 of 28 | USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 3 | Malignant Pancreatic NeoplasmCancer | 24,721 | — | observed | #3 of 28 | C25 | cdc-wonderObserved |
| 4 | Malignant Colon NeoplasmCancer | 19,641 | — | observed | #4 of 28 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 5 | Malignant Ovarian NeoplasmCancer | 12,654 | — | observed | #5 of 28 | C56 | cdc-wonderObserved |
| 6 | Malignant Liver NeoplasmCancer | 10,877 | — | observed | #6 of 28 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 7 | LeukemiaCancer Family | 9,951 | — | observed | #7 of 28 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 8 | Malignant Uterine Corpus NeoplasmCancer | 8,608 | — | observed | #8 of 28 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 9 | Non-Hodgkin LymphomaHematologic Malignancy | 8,450 | — | observed | #9 of 28 | C82-C85, C96 | cdc-wonderObserved |
| 10 | Malignant Central Nervous System NeoplasmCancer | 8,120 | — | observed | #10 of 28 | C70-C72 | cdc-wonderObserved |
| 11 | Malignant Rectal NeoplasmCancer | 5,399 | — | observed | #11 of 28 | C19-C20 | cdc-wonderObserved |
| 12 | Multiple MyelomaHematologic Malignancy | 5,217 | — | observed | #13 of 28 | C88, C90 | cdc-wonderObserved |
| 13 | Malignant Kidney NeoplasmCancer | 5,078 | — | observed | #12 of 28 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 14 | Malignant Bladder NeoplasmCancer | 4,761 | — | observed | #14 of 28 | C67 | cdc-wonderObserved |
| 15 | Malignant Gastric NeoplasmCancer | 4,361 | — | observed | #15 of 28 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 16 | Malignant Cervical NeoplasmCancer | 4,207 | — | observed | #16 of 28 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 17 | Malignant Esophageal NeoplasmCancer | 3,298 | — | observed | #17 of 28 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 18 | Cutaneous MelanomaCancer | 3,073 | — | observed | #18 of 28 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 19 | Malignant Gallbladder NeoplasmCancer | 2,577 | — | observed | no snapshot | C23-C24 | cdc-wonderObserved |
| 20 | Malignant Lip and Oral Cavity NeoplasmCancer | 1,893 | — | observed | no snapshot | C00-C06 | cdc-wonderObserved |
| 21 | Skin CarcinomaCancer | 1,566 | — | observed | no snapshot | C44 | cdc-wonderObserved |
| 22 | Malignant Vulvar NeoplasmCancer | 1,555 | — | observed | #19 of 28 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 23 | Malignant Thyroid Gland NeoplasmCancer | 1,181 | — | observed | #20 of 28 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 24 | Malignant Anal NeoplasmCancer | 1,068 | — | observed | #21 of 28 | C21 | cdc-wonderObserved |
| 25 | Malignant Laryngeal NeoplasmCancer | 826 | — | observed | #22 of 28 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 26 | Malignant Oropharyngeal NeoplasmCancer | 667 | — | observed | no snapshot | C09-C10 | cdc-wonderObserved |
| 27 | Malignant MesotheliomaCancer Family | 574 | — | observed | #23 of 28 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 28 | Malignant Vaginal NeoplasmCancer | 435 | — | observed | #24 of 28 | USCS "Vagina" (ICD-10 C52; ICD-O-3 C529) | cdc-uscsObserved |
| 29 | Malignant Salivary Gland NeoplasmCancer | 391 | — | observed | #25 of 28 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 30 | Hodgkin LymphomaHematologic Malignancy | 358 | — | observed | #26 of 28 | C81 | cdc-wonderObserved |
| 31 | Malignant Nasopharyngeal NeoplasmCancer | 205 | — | observed | #27 of 28 | C11 | cdc-wonderObserved |
| 32 | Malignant Hypopharyngeal NeoplasmCancer | 105 | — | observed | #28 of 28 | C12-C13 | cdc-wonderObserved |
| 33 | Kaposi SarcomaCancer | 16 | — | observed | no snapshot | C46 | cdc-wonderObserved |
| 34 | Malignant Penile NeoplasmCancer | 0 | — | observed | no snapshot | C60 | cdc-wonderObserved |
| 35 | Malignant Prostate NeoplasmCancer | 0 | — | observed | no snapshot | C61 | cdc-wonderObserved |
| 36 | Malignant Testicular NeoplasmCancer | 0 | — | observed | no snapshot | C62 | cdc-wonderObserved |
cdc-wonderProvenance
- Source
- CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)
- Dataset
- CDC WONDER Underlying Cause of Death, 2018-2024, Single Race
- Version
- D158 vintage 2024
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
- Run
- ING-CDCWONDER-20260908-000001
Data updated 21 days agoSource updated D158 vintage 2024
Top cancers
By new cases
2023 — latest year available for this metric (2024 not yet published by the source) · Female · all ages · 29 site groups
| # | Cancer | New cases (count) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Breast NeoplasmCancer Family | 288,494 | — | observed | #1 of 29 | USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 2 | Malignant Lung NeoplasmCancer | 115,875 | — | observed | #2 of 29 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 3 | Malignant Uterine Corpus NeoplasmCancer | 62,434 | — | observed | #3 of 29 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 4 | Malignant Colon NeoplasmCancer | 53,230 | — | observed | #4 of 29 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 5 | Cutaneous MelanomaCancer | 42,934 | — | observed | #5 of 29 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 6 | Malignant Thyroid Gland NeoplasmCancer | 35,906 | — | observed | #6 of 29 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 7 | Non-Hodgkin LymphomaHematologic Malignancy | 33,845 | — | observed | #7 of 29 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 8 | Malignant Pancreatic NeoplasmCancer | 29,538 | — | observed | #8 of 29 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 9 | Malignant Kidney NeoplasmCancer | 27,705 | — | observed | #9 of 29 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 10 | LeukemiaCancer Family | 24,130 | — | observed | #10 of 29 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 11 | Malignant Ovarian NeoplasmCancer | 21,112 | — | observed | #11 of 29 | USCS "Ovary" (ICD-10 C56; ICD-O-3 C569) | cdc-uscsObserved |
| 12 | Malignant Rectal NeoplasmCancer | 19,481 | — | observed | #12 of 29 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 13 | Malignant Bladder NeoplasmCancer | 18,858 | — | observed | #13 of 29 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 14 | Multiple MyelomaHematologic Malignancy | 13,969 | — | observed | #14 of 29 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 15 | Malignant Cervical NeoplasmCancer | 13,222 | — | observed | #15 of 29 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 16 | Malignant Liver NeoplasmCancer | 12,598 | — | observed | #16 of 29 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 17 | Malignant Gastric NeoplasmCancer | 12,253 | — | observed | #17 of 29 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 18 | Malignant Central Nervous System NeoplasmCancer | 10,165 | — | observed | #18 of 29 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 19 | Malignant Anal NeoplasmCancer | 6,275 | — | observed | #19 of 29 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 20 | Malignant Vulvar NeoplasmCancer | 6,103 | — | observed | #20 of 29 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 21 | Malignant Esophageal NeoplasmCancer | 4,349 | — | observed | #21 of 29 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 22 | Hodgkin LymphomaHematologic Malignancy | 3,892 | — | observed | #22 of 29 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 23 | Malignant Laryngeal NeoplasmCancer | 2,472 | — | observed | #23 of 29 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 24 | Malignant Salivary Gland NeoplasmCancer | 2,204 | — | observed | #24 of 29 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 25 | Malignant Vaginal NeoplasmCancer | 1,382 | — | observed | #25 of 29 | USCS "Vagina" (ICD-10 C52; ICD-O-3 C529) | cdc-uscsObserved |
| 26 | Malignant MesotheliomaCancer Family | 783 | — | observed | #26 of 29 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 27 | Malignant Nasopharyngeal NeoplasmCancer | 520 | — | observed | #27 of 29 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 28 | Malignant Hypopharyngeal NeoplasmCancer | 423 | — | observed | #28 of 29 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 29 | Kaposi SarcomaCancer | 98 | — | observed | #29 of 29 | USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site)) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By mortality rate (age-standardized)
2024 · Female · all ages · 36 site groups · 2000 U.S. Std. Population
| # | Cancer | Mortality rate (age-standardized) (per 100,000) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Lung NeoplasmCancer | 24.6 | 24.4–24.8 | observed | #1 of 28 | C33-C34 | cdc-wonderObserved |
| 2 | Malignant Breast NeoplasmCancer Family | 18.7 | 18.6–18.9 | observed | #2 of 28 | C50 | cdc-wonderObserved |
| 3 | Malignant Pancreatic NeoplasmCancer | 10 | 9.9–10.1 | observed | #3 of 28 | C25 | cdc-wonderObserved |
| 4 | Malignant Colon NeoplasmCancer | 8.3 | 8.2–8.4 | observed | #4 of 28 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 5 | Malignant Ovarian NeoplasmCancer | 5.3 | 5.2–5.4 | observed | #5 of 28 | USCS "Ovary" (ICD-10 C56; ICD-O-3 C569) | cdc-uscsObserved |
| 6 | Malignant Liver NeoplasmCancer | 4.4 | 4.3–4.5 | observed | #6 of 28 | C22 | cdc-wonderObserved |
| 7 | LeukemiaCancer Family | 4.2 | 4.1–4.3 | observed | #7 of 28 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 8 | Malignant Central Nervous System NeoplasmCancer | 3.6 | 3.5–3.7 | observed | #8 of 28 | C70-C72 | cdc-wonderObserved |
| 9 | Malignant Uterine Corpus NeoplasmCancer | 3.5 | 3.4–3.6 | observed | #8 of 28 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 10 | Non-Hodgkin LymphomaHematologic Malignancy | 3.4 | 3.4–3.5 | observed | #10 of 28 | C82-C85, C96 | cdc-wonderObserved |
| 11 | Malignant Rectal NeoplasmCancer | 2.3 | 2.3–2.4 | observed | #11 of 28 | C19-C20 | cdc-wonderObserved |
| 12 | Malignant Cervical NeoplasmCancer | 2.1 | 2–2.2 | observed | #12 of 28 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 13 | Malignant Kidney NeoplasmCancer | 2.1 | 2–2.1 | observed | #12 of 28 | C64-C65 | cdc-wonderObserved |
| 14 | Multiple MyelomaHematologic Malignancy | 2.1 | 2–2.1 | observed | #14 of 28 | C88, C90 | cdc-wonderObserved |
| 15 | Malignant Bladder NeoplasmCancer | 1.9 | 1.8–2 | observed | #15 of 28 | C67 | cdc-wonderObserved |
| 16 | Malignant Gastric NeoplasmCancer | 1.9 | 1.9–2 | observed | #15 of 28 | C16 | cdc-wonderObserved |
| 17 | Cutaneous MelanomaCancer | 1.3 | 1.3–1.4 | observed | #17 of 28 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 18 | Malignant Esophageal NeoplasmCancer | 1.3 | 1.3–1.4 | observed | #17 of 28 | C15 | cdc-wonderObserved |
| 19 | Malignant Gallbladder NeoplasmCancer | 1.1 | 1–1.1 | observed | no snapshot | C23-C24 | cdc-wonderObserved |
| 20 | Malignant Lip and Oral Cavity NeoplasmCancer | 0.8 | 0.7–0.8 | observed | no snapshot | C00-C06 | cdc-wonderObserved |
| 21 | Malignant Vulvar NeoplasmCancer | 0.6 | 0.6–0.7 | observed | #19 of 28 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 22 | Skin CarcinomaCancer | 0.6 | 0.6–0.7 | observed | no snapshot | C44 | cdc-wonderObserved |
| 23 | Malignant Thyroid Gland NeoplasmCancer | 0.5 | 0.5–0.5 | observed | #20 of 28 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 24 | Malignant Anal NeoplasmCancer | 0.4 | 0.4–0.5 | observed | #21 of 28 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 25 | Malignant Laryngeal NeoplasmCancer | 0.3 | 0.3–0.4 | observed | #22 of 28 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 26 | Malignant Oropharyngeal NeoplasmCancer | 0.3 | 0.2–0.3 | observed | no snapshot | C09-C10 | cdc-wonderObserved |
| 27 | Hodgkin LymphomaHematologic Malignancy | 0.2 | 0.1–0.2 | observed | #23 of 28 | C81 | cdc-wonderObserved |
| 28 | Malignant MesotheliomaCancer Family | 0.2 | 0.2–0.3 | observed | #23 of 28 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 29 | Malignant Salivary Gland NeoplasmCancer | 0.2 | 0.1–0.2 | observed | #23 of 28 | C07-C08 | cdc-wonderObserved |
| 30 | Malignant Vaginal NeoplasmCancer | 0.2 | 0.1–0.2 | observed | #23 of 28 | C52 | cdc-wonderObserved |
| 31 | Malignant Nasopharyngeal NeoplasmCancer | 0.1 | 0.1–0.1 | observed | #27 of 28 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 32 | Kaposi SarcomaCancer | 0 | 0–0 | observed | no snapshot | C46 | cdc-wonderObserved |
| 33 | Malignant Hypopharyngeal NeoplasmCancer | 0 | 0–0.1 | observed | #28 of 28 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 34 | Malignant Penile NeoplasmCancer | 0 | 0–0 | observed | no snapshot | C60 | cdc-wonderObserved |
| 35 | Malignant Prostate NeoplasmCancer | 0 | 0–0 | observed | no snapshot | C61 | cdc-wonderObserved |
| 36 | Malignant Testicular NeoplasmCancer | 0 | 0–0 | observed | no snapshot | C62 | cdc-wonderObserved |
cdc-wonderProvenance
- Source
- CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)
- Dataset
- CDC WONDER Underlying Cause of Death, 2018-2024, Single Race
- Version
- D158 vintage 2024
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
- Run
- ING-CDCWONDER-20260908-000001
Data updated 21 days agoSource updated D158 vintage 2024
Top cancers
By incidence rate (age-standardized)
2023 — latest year available for this metric (2024 not yet published by the source) · Female · all ages · 29 site groups · 2000 U.S. standard population (19 age groups)
| # | Cancer | Incidence rate (age-standardized) (per 100,000) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Breast NeoplasmCancer Family | 135.2 | 134.7–135.7 | observed | #1 of 29 | USCS "Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 2 | Malignant Lung NeoplasmCancer | 47.3 | 47–47.6 | observed | #2 of 29 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 3 | Malignant Uterine Corpus NeoplasmCancer | 27.8 | 27.5–28 | observed | #3 of 29 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 4 | Malignant Colon NeoplasmCancer | 24.1 | 23.9–24.3 | observed | #4 of 29 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 5 | Cutaneous MelanomaCancer | 20.4 | 20.2–20.6 | observed | #5 of 29 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 6 | Malignant Thyroid Gland NeoplasmCancer | 20 | 19.8–20.2 | observed | #6 of 29 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 7 | Non-Hodgkin LymphomaHematologic Malignancy | 15 | 14.9–15.2 | observed | #7 of 29 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 8 | Malignant Kidney NeoplasmCancer | 12.6 | 12.4–12.7 | observed | #8 of 29 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 9 | Malignant Pancreatic NeoplasmCancer | 12.4 | 12.3–12.6 | observed | #9 of 29 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 10 | LeukemiaCancer Family | 11.2 | 11–11.3 | observed | #10 of 29 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 11 | Malignant Ovarian NeoplasmCancer | 10 | 9.9–10.2 | observed | #11 of 29 | USCS "Ovary" (ICD-10 C56; ICD-O-3 C569) | cdc-uscsObserved |
| 12 | Malignant Rectal NeoplasmCancer | 9.4 | 9.3–9.6 | observed | #12 of 29 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 13 | Malignant Bladder NeoplasmCancer | 7.8 | 7.7–7.9 | observed | #13 of 29 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 14 | Malignant Cervical NeoplasmCancer | 7.5 | 7.3–7.6 | observed | #14 of 29 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 15 | Multiple MyelomaHematologic Malignancy | 6 | 5.9–6.1 | observed | #15 of 29 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 16 | Malignant Gastric NeoplasmCancer | 5.5 | 5.4–5.6 | observed | #16 of 29 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 17 | Malignant Liver NeoplasmCancer | 5.3 | 5.2–5.4 | observed | #17 of 29 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 18 | Malignant Central Nervous System NeoplasmCancer | 5 | 4.9–5.1 | observed | #18 of 29 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 19 | Malignant Anal NeoplasmCancer | 2.7 | 2.7–2.8 | observed | #19 of 29 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 20 | Malignant Vulvar NeoplasmCancer | 2.7 | 2.6–2.8 | observed | #19 of 29 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 21 | Hodgkin LymphomaHematologic Malignancy | 2.2 | 2.1–2.3 | observed | #21 of 29 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 22 | Malignant Esophageal NeoplasmCancer | 1.8 | 1.8–1.9 | observed | #22 of 29 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 23 | Malignant Laryngeal NeoplasmCancer | 1.1 | 1–1.1 | observed | #23 of 29 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 24 | Malignant Salivary Gland NeoplasmCancer | 1.1 | 1–1.1 | observed | #23 of 29 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 25 | Malignant Vaginal NeoplasmCancer | 0.6 | 0.6–0.6 | observed | #25 of 29 | USCS "Vagina" (ICD-10 C52; ICD-O-3 C529) | cdc-uscsObserved |
| 26 | Malignant MesotheliomaCancer Family | 0.3 | 0.3–0.4 | observed | #26 of 29 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 27 | Malignant Nasopharyngeal NeoplasmCancer | 0.3 | 0.2–0.3 | observed | #26 of 29 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 28 | Malignant Hypopharyngeal NeoplasmCancer | 0.2 | 0.2–0.2 | observed | #28 of 29 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 29 | Kaposi SarcomaCancer | 0 | 0–0.1 | observed | #29 of 29 | USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site)) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Trend
Mortality rate (age-standardized) — top 8 cancers, all years
Top cancers of 2024 (Female) traced over every year published for United States. Dashed lines mark estimated or projected values; the y axis starts at zero.
cdc-uscsObservedstandard: 2000 U.S. standard population (19 age groups)264 points
Clinical research
Clinical trial activity in United States
Registrant-entered study locations on ClinicalTrials.gov mapped to this country (any study type, any phase). A site is one location; a multi-site study weighs by its number of sites. Recruiting = location status RECRUITING, or the study status when the site has none.
- Sites
- 609,712
- Studies with a site here
- 50,881
- Recruiting sites
- 71,558
- Recruiting studies
- 7,743
Computed formula ci-trial-sites-v1 · source: clinicaltrials · shares are of sites, not of studies
Data updated 18 hours agoSource updated unknowntrial_site_country_counts
Regulatory
Oncology approval records · US
Records of the country's regulator as ingested (one record = one decision for one application or product identifier). Absence of a record here is not evidence of absence.
FDA · approved: 2,343 records / 304 drugs
- Sep 18, 2026Abemaciclib approved cancer not stated in this recordEfficacy supplement 2026-09-18 (see label)openfda
- Sep 9, 2026Aminolevulinic Acid approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
- Sep 9, 2026Sevabertinib approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
- Sep 4, 2026Camizestrant approved Malignant Breast Neoplasmin combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor…openfda
- Aug 28, 2026Ropeginterferon Alfa-2b approved cancer not stated in this recordEfficacy supplement 2026-08-28 (see label)openfda
- Aug 25, 2026Zanidatamab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
- Aug 25, 2026Tislelizumab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
- Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
- Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
- Jul 14, 2026Selpercatinib approved cancer not stated in this recordEfficacy supplement 2026-07-14 (see label)openfda
Regulatory
Provenance
Sources and freshness
What each source covers for this geography, exactly as ingested. Values are normalized (units, labels) but never changed.
| Source | Metric | Sex | Years | Cancers | Estimate types | Standard population | Ingested |
|---|---|---|---|---|---|---|---|
| cdc-uscs | Incidence rate (age-standardized) | Both | 1999–2023 (25) | 24 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Incidence rate (age-standardized) | Female | 1999–2023 (25) | 29 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Incidence rate (age-standardized) | Male | 1999–2023 (25) | 27 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Both | 1999–2024 (26) | 23 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Both | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Female | 1999–2024 (26) | 28 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Female | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Male | 1999–2024 (26) | 26 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Male | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | New cases | Both | 1999–2023 (25) | 32 | observed | — | 2026-09-08 |
| cdc-uscs | New cases | Female | 1999–2023 (25) | 29 | observed | — | 2026-09-08 |
| cdc-uscs | New cases | Male | 1999–2023 (25) | 27 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Both | 1999–2024 (26) | 31 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Both | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Female | 1999–2024 (26) | 28 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Female | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Male | 1999–2024 (26) | 26 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Male | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Both | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Female | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Male | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortalitylicense: approvedUS Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)license: approvedUS Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
Age-standardized rates use the 2000 U.S. standard population (19 age groups); they are not comparable with rates standardized to the World (Segi) population used by IARC. Global comparisons are not available: the IARC Global Cancer Observatory remains under license review and the SEER API awaits credentials (CLAUDE.md §10.3-10.4). Only geographies with licensed observations get a page; see /countries.
Data updated 21 days agoSource updated 1999–202410,680 observations approx. · ranks from snapshots geo=USA